ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC announces that a securities class action lawsuit has been filed against Seres Therapeutics, Inc. (“Seres Therapeutics” or the “Company”) (NASDAQ: MCRB) on behalf of investors that purchased its common stock between June 25, 2015 and July 29, 2016. Investors who wish to file a motion to become the lead plaintiff in the litigation must do so not later than November 29, 2016.
The lawsuit alleges Seres Therapeutics omitted material facts when discussing the potential and efficacy of its drug candidate SER-109. On July 29, 2016, Seres Therapeutics announced the Phase 2 clinical trial of SER-109 did not achieve its primary endpoint.
If you purchased Seres Therapeutics common stock between June 25, 2015 and July 29, 2016 and suffered a significant loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at firstname.lastname@example.org or Marshall P. Dees, Esq., at email@example.com, or via toll-free telephone at (888) 508-6832, to discuss your legal rights before the lead plaintiff deadline of November 29, 2016.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.